Study of Poziotinib in Japanese Patients With NSCLC
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
A Phase 1/2, open-label, multicenter study to determine dose, tolerability, safety and
efficacy of poziotinib in Japanese patients non-small cell lung cancer (NSCLC).